Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
NCT ID: NCT04915235
Last Updated: 2021-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2087 participants
OBSERVATIONAL
2020-09-18
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Amyloidosis in HFpEF Tunisian Patients
NCT06201832
Prevalence of Amyloidosis in Heart Failure (PREVAMIC)
NCT04066452
ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey
NCT07238426
Early Detection of Cardiac Amyloidosis
NCT05010980
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
NCT01623245
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Algorithm
Algorithm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with left ventricular hypertrophy and hypertension or aortic stenosis without left ventricular pressure or volume (IVS\>15mm)
Exclusion Criteria
* Patients with sigmoid septum and their hypertrophy limited in sigmoid area
* Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LV morhpology and genetic testing
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turkish Society of Cardiology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dokuz Eylul University Faculty of Medicine
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ebru Ozpelit, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PAPCAT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.